皮皮学,免费搜题
登录
logo - 刷刷题
搜题
【单选题】
Michael Porter, who has made his name throughout the business community by advocating his theories of competitive advantages, is now swimming into even more shark-infested waters, arguing that competition can save even America's troubled health-care system, the largest in the world. Mr. Porter argues in 'Redefining Health Care' that competition, if properly applied, can also fix what ails this sector. That is a bold claim, given the horrible state of America's health-care system. Just consider a few of its failings: America pays more per capita for health care than most countries, but it still has some 45m citizens with no health insurance at all. While a few receive outstanding treatment, he shows in heart-wrenching detail that most do not. The system, wastes huge resources on paperwork, ignores preventive care and, above all, has perverse incentives that encourage shifting costs rather than cutting them outright. He concludes that it is 'on a dangerous path, with a toxic combination of high costs, uneven quality, frequent errors and limited access to care'. Many observers would agree with this diagnosis, but many would undoubtedly disagree with this advocacy of more market forces. Doctors have an intuitive distrust of competition, which they often equate with greed, while many public-policy thinkers argue that the only way to fix America's problem is to quash the private sector's role altogether and instead set up a government monopoly like Britain's National Health Service. Mr. Porter strongly disagrees. He starts by acknowledging that competition, as it has been introduced to America's health system, has in fact done more harm than good. But he argues that competition has been introduced piecemeal, in incoherent and counter-productive ways that lead to perverse incentives and worse outcomes: 'health-care competition is not focused on delivering value for patients', he says. Mr. Porter offers a mix of solutions to fix this mess, and thereby to put the sector on a genuinely competitive footing. First comes the seemingly obvious (but as yet unrealized) goal of data transparency. Second is a redirection of competition from the level of health plans, doctors, clinics and hospitals, to competition 'at the level of medical conditions, which is all but absent'. The authors argue that the right measure of 'value' for the health sector should be how well a patient with a given health condition fares over the entire cycle of treatment, and what the cost is for that entire cycle. That rightly emphasizes the role of early detection and preventive care over techno-fixes, pricey pills and the other failings of today's system. If there is a failing in this argument, it is that he sometimes strays toward naive optimism. Mr. Porter argues, for example, that his solutions are so commonsensical that private actors in the health system could forge ahead with them profitably without waiting for the government to fix its policy mistakes. That is a tempting notion, but it falls into a trap that economists call the fallacy of the $20 bill on the street. If there really were easy money on the pavement, goes the argument, surely previous passers-by would have bent over and picked it up by now. In the same vein, if Mr. Porter's prescriptions are so sensible that companies can make money even now in the absence of government policy changes, why in the world have they not done so already? One reason may be that they can make more money in the current suboptimal equilibrium than in a perfectly competitive market—which is why government action is probably needed to sweep aside the many obstacles in the way of Mr. Porter's powerful vision. What seems to be the biggest problem with America's health care system?
A.
American spends more money on health care than on other services.
B.
Most Americans couldn't get their health insurance till their old age.
C.
Most American hospitals do not offer outstanding treatment to patients.
D.
The costs of health care are not steered towards a health direction.
手机使用
分享
复制链接
新浪微博
分享QQ
微信扫一扫
微信内点击右上角“…”即可分享
反馈
参考答案:
举一反三
【多选题】热解过程中热解产物错综复杂,因此在分析中多数考虑其表观动力学,用质谱连用仪分析含氧氛围下的热解产物,包括下列 ( ) 产物 。
A.
B.
CO和CO 2
C.
甲醛和乙酸 /乙醇醛
D.
1-羟基丙酮、糠醛和5-甲基糠醛
【单选题】缺血再灌注损伤是
A.
缺血后恢复血流灌注引起的后果
B.
缺血后恢复血流后引起更剧烈的损伤
C.
无钙后用含钙溶液灌注引起的组织损伤
D.
缺氧后用富含氧溶液灌注引起的组织损伤
E.
是缺血的延续
【判断题】持续经营假设可使企业成为百年老店,因而即使企业进入破产清算,也不应该改变会计核算方法。
A.
正确
B.
错误
【单选题】下列关于心肌缺血再灌注损伤的描述错误的是()
A.
缺血再灌注损伤心肌又称晕厥心肌
B.
缺血再灌注损伤心肌的收缩功能严重受损
C.
缺血再灌注损伤心肌的舒张功能不受影响
D.
心肌缺血再灌注损伤主要与钙超载有关
E.
能量代谢障碍也是其发病机制之一
【简答题】三相笼式异步电动机的制动方式有哪些?
【单选题】机外刀具预调测量仪可以( )。[单选题]
A.
测量、设定工件坐标系
B.
测量、设定机床坐标系
C.
测量刀具相对工件的位置
D.
测量各刀具之间的相对长度
【单选题】缺血再灌注损伤是指()
A.
缺血后引起的损伤
B.
再灌注后引起的损伤
C.
缺血后恢复血流引起的后果
D.
缺血后恢复血流损伤加重
E.
以上都不是
【判断题】EDTA属于氨羧配位剂。
A.
正确
B.
错误
【简答题】笼型异步电动机制动方式有 、 。
【单选题】机外刀具预调测量仪可以( )。
A.
测量、设定工件坐标系
B.
测量、设定机床坐标系
C.
测量刀具相对工件的位置
D.
测量各刀具之间的相对长度
相关题目:
参考解析:
知识点:
题目纠错 0
发布
创建自己的小题库 - 刷刷题